Omid Veiseh is an American biomaterials researcher and entrepreneur. As a postdoctorate candidate at MIT, he co-founded Siglion Therapeutics, a biotechnology company which would commercialize the discoveries he and his co-founders developed. In 2016, Veiseh was offered a faculty position in the Department of Bioengineering at Rice University.
Omid Veiseh | |
|---|---|
| Academic background | |
| Education | BS, Western Washington University PhD, Materials Science and Engineering and Nanotechnology, 2009, University of Washington, PostDoc, MIT |
| Academic work | |
| Institutions | Rice University |
| Website | veisehlab |
Early life and education
editVeiseh earned his Bachelor of Science degree from Western Washington University and his PhD from the University of Washington.[1] Upon completing his PhD, Veiseh completed his post-doctoral research at MIT's Koch Institute for Integrative Cancer Research where he co-developed a way to reduce immune-system rejection using biomedical devices.[2] While at MIT, he co-founded Sigilon Therapeutics, a biotechnology company which would commercialize the discoveries he and his co-founders developed.[3]
Career
editVeiseh left MIT in 2016, after Rice University won a $2 million grant from the Cancer Prevention and Research Institute of Texas to recruit him to their Department of Bioengineering.[4] As an assistant professor of bioengineering, Veiseh and his laboratory earned funding from the National Institutes of Health to design hydrogel-encapsulated cells can sense blood glucose levels and produce insulin on demand.[5] He also collaborated with Jordan Miller to combine cell-based therapy applications with 3D-printed technologies for use in Type-1 diabetes therapies.[3]
While at Rice, Veiseh's Sigilon Therapeutics partnered with Eli Lilly and Company to develop "living drug factories" that could be safely implanted in the body and produce insulin.[6] As a result of his efforts, Veiseh was recognized by MedTech Boston on their 40 under 40 Healthcare Innovators in 2017.[7] Individually, he also worked alongside Ravi Ghanta to develop a novel biomaterial improve the cells’ ability to heal heart injuries.[8]
References
edit- ^ "Omid Veiseh". profiles.rice.edu. Retrieved December 28, 2020.
- ^ Trafton, Anne (May 18, 2015). "Designing better medical implants". news.mit.edu. Retrieved December 28, 2020.
- ^ a b Hutchins, Shawn (September 18, 2018). "Rice University bioengineers combine forces to fight Type-1 diabetes". bioengineering.rice.edu. Retrieved December 28, 2020.
- ^ Boyd, Jane (June 6, 2016). "Rice wins award to recruit cancer researcher". rice.edu. Retrieved December 28, 2020.
- ^ Williams, Mike (October 8, 2018). "Rice pursues endgame for diabetes". news.rice.edu. Retrieved December 28, 2020.
- ^ Matheson, Rob (May 16, 2018). ""Living drug factories" may one day replace injections". news.mit.edu. Retrieved December 28, 2020.
- ^ "27. Omid Veiseh, Ph.D. Co-Founder and Head of Innovation at Sigilon, Inc". medtechboston.medstro.com. 2017. Retrieved December 28, 2020.
- ^ "Heart attack damage reduced by shielded stem cells". technology.org. August 24, 2020. Retrieved December 28, 2020.
External links
editOmid Veiseh publications indexed by Google Scholar